Instem plc Notice of AGM & Posting of Annual Report (4896B)
June 02 2023 - 3:51AM
UK Regulatory
TIDMINS
RNS Number : 4896B
Instem plc
02 June 2023
Instem plc
("Instem", or the "Company")
Notice of AGM
Posting of Annual Report
Instem plc (AIM: INS), a leading p rovider of IT solutions to
the global life sciences market, announces that it has posted to
shareholders its Annual Report and Accounts for the year ended 31
December 2022, together with the Notice of Annual General Meeting
which is to be held at the offices of the Company at 2 Diamond Way,
Stone Business Park, Stone, Staffordshire, ST15 0SD on 27(th) June
2023 at 2.30 p.m.
A copy of the Annual Report and Accounts and Notice of Annual
General meeting is available on Instem's website.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0) 20 7710 7600
Ben Maddison
Richard Short
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Joe Walker
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management, Regulatory Submissions, Clinical Trial Acceleration,
and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all of the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform during their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
About eTRANSAFE
The "Enhancing TRANslational SAFEty Assessment through
Integrative Knowledge Management (eTRANSAFE)" project develops an
integrative data infrastructure and innovative computational
methods and tools that aim to drastically improve the feasibility
and reliability of translational safety assessment during the drug
development process. This infrastructure will be underpinned by
development of open standards and robust policies widely accepted
by stakeholders, including regulatory agencies and international
organisations.
The eTRANSAFE is a 5.5-year project, started on 1st September of
2017, funded by the Innovative Medicines Initiative 2 Joint
Undertaking (IMI 2) together with the pharmaceutical industry, that
aims to develop an advanced data integration infrastructure
together with innovative computational methods to improve the
security in drug development process.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSUUSBROKUNRRR
(END) Dow Jones Newswires
June 02, 2023 03:51 ET (07:51 GMT)
Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024
Instem (LSE:INS)
Historical Stock Chart
From Jun 2023 to Jun 2024
